TY - JOUR
T1 - The Influence of Pre-Analytical Factors on the Analysis of Circulating MicroRNA
AU - Shiotsu, Hiromichi
AU - Okada, Kazuhiro
AU - Shibuta, Tatsuki
AU - Kobayashi, Yuki
AU - Shirahama, Saki
AU - Kuroki, Chieri
AU - Ueda, Saori
AU - Ohkuma, Masanori
AU - Ikeda, Katsuyoshi
AU - Ando, Yukio
AU - Matsui, Hirotaka
AU - Kayamori, Yuzo
AU - Umemura, Tsukuru
N1 - Publisher Copyright:
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
PY - 2018
Y1 - 2018
N2 - BACKGROUND: MicroRNAs (miRNA) are expected as useful biomarkers for various diseases. We studied the pre-analytical factors causing variation in the analysis of miRNA. MATERIAL AND METHODS: Blood samples were collected from 25 healthy subjects. Plasma and serum were obtained from the same samples. The levels of miR-451, -16, -126, and -223 were analyzed using RT-qPCR. Cel-miR-39 was added as a spiked-in control in each sample. RESULTS: With the exception of miR-451, the levels of the miRNAs in plasma were higher than in serum. After high-speed centrifugation, the levels of miRNAs were almost equal between plasma and serum except for miR-451. Membrane filtration with 0.45 µm pore size reduced the levels of plasma miRNAs. The coagulation accelerators for serum processing did not affect the analysis of miRNA. The use of fraction containing particles of > 0.45 µm in size showed the inhibitory effect on the analysis of plasma miR-451. The RNase inhibitor was effective for protecting against the degradation of miRNAs. CONCLUSION: Plasma contains factors modifying miRNA profiles. The immediate processing of plasma with membrane filtration and RNase inhibitor may be a relevant method for achieving the stable analysis of miRNA.
AB - BACKGROUND: MicroRNAs (miRNA) are expected as useful biomarkers for various diseases. We studied the pre-analytical factors causing variation in the analysis of miRNA. MATERIAL AND METHODS: Blood samples were collected from 25 healthy subjects. Plasma and serum were obtained from the same samples. The levels of miR-451, -16, -126, and -223 were analyzed using RT-qPCR. Cel-miR-39 was added as a spiked-in control in each sample. RESULTS: With the exception of miR-451, the levels of the miRNAs in plasma were higher than in serum. After high-speed centrifugation, the levels of miRNAs were almost equal between plasma and serum except for miR-451. Membrane filtration with 0.45 µm pore size reduced the levels of plasma miRNAs. The coagulation accelerators for serum processing did not affect the analysis of miRNA. The use of fraction containing particles of > 0.45 µm in size showed the inhibitory effect on the analysis of plasma miR-451. The RNase inhibitor was effective for protecting against the degradation of miRNAs. CONCLUSION: Plasma contains factors modifying miRNA profiles. The immediate processing of plasma with membrane filtration and RNase inhibitor may be a relevant method for achieving the stable analysis of miRNA.
UR - http://www.scopus.com/inward/record.url?scp=85058446498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058446498&partnerID=8YFLogxK
U2 - 10.2174/2211536607666180709143335
DO - 10.2174/2211536607666180709143335
M3 - Article
C2 - 29984665
AN - SCOPUS:85058446498
SN - 2211-5366
VL - 7
SP - 195
EP - 203
JO - MicroRNA (Shariqah, United Arab Emirates)
JF - MicroRNA (Shariqah, United Arab Emirates)
IS - 3
ER -